Reaktion #85482

ord-d395206a7be74ea08d53025217de591a

Reaktionsbedingungen

Detaillierte Bedingungen
See reaction.notes.procedure_details.

Aufarbeitung

  1. 1
    SonstigeThe two phases were then separated
  2. 2
    Extraktionthe aqueous phase was extracted once more with ethyl acetate (1×)
  3. 3
    WaschenThe combined organic phase was washed with water (1×) and saturated sodium chloride solution (1×)
  4. 4
    Trocknendried over magnesium sulfate
  5. 5
    Filtrationfiltered
  6. 6
    Sonstigethe solvent was evaporated in vacuo
  7. 7
    SonstigeThe residue was purified by preparative HPLC (RP, eluents acetonitrile/water, 0.01% TFA)

Vorschrift

16.3 mg (0.41 mmol, 60% w/w) of sodium hydride and, after 10 minutes, 96 mg (0.41 mmol) of 2,4-dimethoxyphenylsulfonyl chloride were added to a solution, cooled to 0° C., of 180 mg (0.34 mmol) of 5-chloro-3-(2-ethoxypyridin-3-yl)-6-fluoro-3-{2-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]-2-oxo-ethyl}-1,3-dihydroindol-2-one in 2 ml of dimethylformamide. The reaction mixture was allowed to warm to room temperature and was stirred for a further 50 minutes. The progress of the reaction was followed by thin-layer chromatography (silica gel, dichloromethane/methanol 15:5). Water and ethyl acetate were added to the reaction mixture. The two phases were then separated and the aqueous phase was extracted once more with ethyl acetate (1×). The combined organic phase was washed with water (1×) and saturated sodium chloride solution (1×), dried over magnesium sulfate and filtered, and the solvent was evaporated in vacuo. The residue was purified by preparative HPLC (RP, eluents acetonitrile/water, 0.01% TFA). 116 mg (0.16 mmol, 46%, 99% purity) of the title compound were obtained as a white solid.

Quelle

DOI: 10.6084/m9.figshare.5104873.v1Patent: US09434713B2uspto-grants-2016_09